Physician profile
Steven Koerth
NPI 1124023130
$8,625.78
in general payments reported to CMS, 2019-2025
40 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $858 · 2021: $1,527 · 2022: $1,459 · 2023: $1,544 · 2024: $1,375 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $875.30 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $866.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $821.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.48 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $679.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $597.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $539.21 | 2019-2025 | Tymlos |
| Mylan Specialty L.P. | $419.79 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $416.89 | 2021-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $391.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.21 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $214.08 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $185.12 | 2021-2024 | |
| Horizon Therapeutics Plc | $179.98 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.46 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Koerth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.